Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Business Wire
– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 –– Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 –– GAAP Diluted EPS of $0.88 for the Fourth Quarter of 2025, $2.78 for the Fiscal Year 2025 –– Conference Call and Webcast Today at 5:00 PM Eastern Time – ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.“Exelixis delivered strong results in 2025 and is well positioned for a breakout year in 2026,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “The cabozantinib franchise continued to grow with robust demand in renal cell carcinoma and neuroendocri
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Exelixis, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $46.00. They now have a "sector perform" rating on the stock.MarketBeat
- Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Wells Fargo & Company from $30.00 to $35.00. They now have an "equal weight" rating on the stock.MarketBeat
- Exelixis (NASDAQ:EXEL) was given a new $44.00 price target on by analysts at Stifel Nicolaus.MarketBeat
EXEL
Earnings
- 2/10/26 - Beat
EXEL
Sec Filings
- 2/13/26 - Form 144
- 2/13/26 - Form 144
- 2/13/26 - Form 144
- EXEL's page on the SEC website